Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients
Status:
Terminated
Trial end date:
2021-06-09
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess safety, tolerability, pharmacokinetics, and
pharmacodynamics of M254 after administration of a single ascending dose and repeat doses in
healthy volunteers and immune thrombocytopenic purpura (ITP) patients. The pharmacodynamics
of the drug will be measured as platelet response in patients with ITP.